These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12063979)

  • 1. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.
    Miyaguchi S; Watanabe T; Takahashi H; Nakamura M; Saito H; Ishii H
    Hepatogastroenterology; 2002; 49(45):724-9. PubMed ID: 12063979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Shiratori Y; Shiina S; Teratani T; Imamura M; Obi S; Sato S; Koike Y; Yoshida H; Omata M
    Ann Intern Med; 2003 Feb; 138(4):299-306. PubMed ID: 12585827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
    Chen LT; Chen MF; Li LA; Lee PH; Jeng LB; Lin DY; Wu CC; Mok KT; Chen CL; Lee WC; Chau GY; Chen YS; Lui WY; Hsiao CF; Whang-Peng J; Chen PJ;
    Ann Surg; 2012 Jan; 255(1):8-17. PubMed ID: 22104564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group.
    Lancet; 1998 May; 351(9115):1535-9. PubMed ID: 10326535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Hung CH; Lee CM; Wang JH; Tung HD; Chen CH; Lu SN
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1553-9. PubMed ID: 16174073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
    Dohmen K; Shirahama M; Shigematsu H; Miyamoto Y; Torii Y; Irie K; Ishibashi H
    Hepatogastroenterology; 2001; 48(41):1409-15. PubMed ID: 11677976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
    Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
    Mazzaferro V; Romito R; Schiavo M; Mariani L; Camerini T; Bhoori S; Capussotti L; Calise F; Pellicci R; Belli G; Tagger A; Colombo M; Bonino F; Majno P; Llovet JM;
    Hepatology; 2006 Dec; 44(6):1543-54. PubMed ID: 17133492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation.
    Sheiner PA; Boros P; Klion FM; Thung SN; Schluger LK; Lau JY; Mor E; Bodian C; Guy SR; Schwartz ME; Emre S; Bodenheimer HC; Miller CM
    Hepatology; 1998 Sep; 28(3):831-8. PubMed ID: 9731580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.
    Mazzella G; Accogli E; Sottili S; Festi D; Orsini M; Salzetta A; Novelli V; Cipolla A; Fabbri C; Pezzoli A; Roda E
    J Hepatol; 1996 Feb; 24(2):141-7. PubMed ID: 8907566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Scand J Gastroenterol; 2005 Jun; 40(6):688-96. PubMed ID: 16036529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.